Skip to main content
. 2022 Mar 11;15(3):345. doi: 10.3390/ph15030345

Figure 1.

Figure 1

(a) Workout time (mean ± SEM) of patients in group A (ADAPT-232) and group B (placebo) over the time from Day 1 to Day 21. The changes from the baseline within groups A and B over time were significant (p < 0.0001; calculated by repeated measures ANOVA); two-way ANOVA estimated the significant interaction between treatment groups over time; *—p = 0.0148. (b) Between-groups comparison of the changes of workout from the baseline over time shows significant interaction (p < 0.0001) and very significant difference (p < 0.0001) between groups A and B. The ADAPT-232 treatment significantly increases patients’ workouts compared to placebo. ***—p< 0.001. For details of statistical analysis, see Supplement 2.